New drug combo aims to fight tough lung cancer
NCT ID NCT04919382
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This phase II trial is testing whether combining the chemotherapy drug temozolomide with the immunotherapy atezolizumab can help shrink tumors or slow the disease in people with advanced small cell lung cancer that has spread or returned. About 56 participants will receive the combination as a second or third treatment option. The study will measure how many patients respond and track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
Contact Email: •••••@•••••
Contact
-
University of Iowa Hospitals and Clinics
RECRUITINGIowa City, Iowa, 52242, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
temozolomide (chemotherapy) and atezolizumab (immunotherapy)
What this could lead to
If successful, this combination could offer a new treatment option to help shrink tumors or slow progression in patients with advanced small cell lung cancer who have already tried other therapies.
What could go wrong
This is an early phase II trial with only 56 participants, so results may not apply to all patients. The combination may cause side effects like immune-related reactions or low blood counts, and it is not yet proven to extend survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.